The FDA accepted uniQure’s AMT-130 application for quick review, but has not approved the treatment, and a follow-up study remains to be carried out. Revenue growth and cash expected to last into 2030 support a positive outlook.
This gives uniQure a clearer route toward a possible U.S. launch, but the treatment is not approved yet. Cash expected to last into 2030 gives the company time to prepare. It still needs to carry out a follow-up study to check the treatment.
Follow uniQure (QURE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for QURE